About Us
We are an unparalleled biopharmaceutical company.
History
2011 ~ Present
- 2022
- 07Merger and listing on KOSPI
- 12 Affiliated company, Aprogen Pharmaceuticals, Merger with 'Aprogen Biologics'
- 2021
- 11Started commercialization of GS071
- 08Appointed Seungho Rhee as CEO
- 07Completed phase nonclinical trials for AP096
- 03Completed phase nonclinical trials for AP056
- 2020
- 01Obtained domestic Food and Drug Safety (MFDS) cGMP certification
- 01First Korean Biopharmaceutical Company to be listed as a Unicorn
(private ventures with $1 billion+ in valuations) - 01Osong Plant Expansion
- 2019
- 09Completed phase 3 clinical trials for GS071 in US
- 05Completed phase 1 clinical trials for AP063 in US
- 2018
- 04Completed construction of Osong Plant
- 2017
- 09Received approval of GS071 for Japan (PMDA)
- 2016
- 07Started Osong Plant construction
- 05Acquired Innovative SME Certificate (Inno-Biz) from Ministry of SMEs and Startups
- 05Acquired R&D Venture Enterprise Certificate from Korea Technology Finance Corporation
- 2015
- 10Submitted MAA (Marketing Authorization Application) for GS071 to the PMDA
- 09Completed phase 3 clinical trials for GS071 in Japan
- 06Contracted long-term supply agreement for GS071 with Nichi-Iko Pharmaceuticals Co., Ltd.
- 03Relocated headquarters to B1, Halla Sigma Valley, 545, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do
- 2014
- 04Established Aprogen Biologics Inc. for constructing Osong Plant
- 02Contracted global license rights for GS071 with Nichi-Iko Pharmaceuticals Co., Ltd.
- 2012
- 11Relocated headquarters to Inno-Biz Park, Hannam University
- 11Completed phase 1 clinical trials for GS071 in Japan
- 10Acquired property for Osong Plant in Osong Biovalley, Chungbuk
- 03Completed phase 1 clinical trials for GS071 Korea
- 2011
- 11Signed agreement between Schnell Life Sciences Inc. and Binex Co., Ltd. for joint pursue of license for GS071 in Russia, Turkey, and the Middle East
- 08Contracted AP063 distribution rights for Korea to Schnell Life Sciences Inc.
- 03Finished construction and relocated R&D labs and clinical scale production facility to Seongnam
- 03Received 2nd round of funding from Nichi-Iko Pharmaceuticals Co., Ltd.
- About Us Privacy Policy Inquiries Sitemap
-
Company Infomation
Aprogen
545, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13215
Contact : +82-31-625-4045
-
Aprogen
545, Dunchon-daero, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea, 13215
Contact : +82-31-625-4045 - copyright(c) by APROGEN. All Right Reserved.